Posted by Michael Wonder on 20 Oct 2025
Fast track granted by FDA for NNZ-2591 in Phelan-McDermid syndrome
20 October 2025 - Neuren Pharmaceuticals today announced that the US FDA has granted fast track designation for NNZ-2591 for the treatment of Phelan-McDermid syndrome.
Currently there are no FDA approved treatments for Phelan-McDermid syndrome.
